Pharmacogenetic Testing

Clinically Actionable Pharmacogenetic Tests to Determine Right Medication and Dosage

Pharmacogenetic Testing allows us to assess the likelihood that an individual will have normal, reduced or enhanced response to certain medications. This is very important because it dictates how a person responds to a treatment prior to actually receiving the treatment based on genetics, improving efficacy and reducing adverse effects.

Actionable Pharmacogenetic Biomarkers Identify Genetic Fingerprints to Help Determine the Tailored Treatment Plan

ABCB1
APOE
COMT
CYP1A2,
CYP2C19
CYP2C9
CYP2D6
CYP1A2
CYP2B6
CYP3A4
CYP3A5
DRD2
Factor II
Factor V
GLP1R
MTHFR
OPRM1
PNPLA5
SLCO1B1
SULT4A1
VKORC1
APOE
CYP2C19
CYP2C9
CYP2D6
CYP3A4
Factor II
Factor V
MTHFR
SLCO1B1
VKORC1
COMT
CYP1A2
CYP2C19
CYP2C9
CYP2D6
CYP2B6,
DRD2
GLP1R
MTHFR
OPRM1,
PNPLA5
SULT4A1
COMT
CYP1A2
CYP2C19
CYP2C9
CYP2D6
OPRM1
CYP2C19
CYP3A5
CYP2C9
CYP2D6
MTHFR
Factor II
Factor V
VKORC1
Factor II
Factor V
MTHFR
5-HT2A C>T_____Serotonin 2A Receptor__________rs7997012
COMT _________Catechol-O-Methyltransferase_____rs4680
DRD2 G>A______Dopamine D2 Receptor__________rs1800497
DRD1 A>G______Dopamine D1 Receptor__________rs4532
DRD4 T>C______Dopamine D4 Receptor__________rs3758653
DAT1 A>G______Dopamine Transporter___________rs6347
DBH C>T_______Dopamine Beta Hydroxylase_______rs1611115
MTHFR C>T_____Methylene Tetrahydrofolate_______rs1801133
_______________Reductase
OPRK1 G>T______Kappa Opioid Receptor__________rs1051660
GABA C>A_______Gamma-Aminibutyric Acid (GABA)_rs211014
OPRM1 A>G_____Mu Opioid Receptor_____________rs1799971
MUOR G>A______Mu Opioid Receptor____________rs9479757
GAL T>C________Galanin______________________rs948854
DOR G>A_______Delta Opioid Receptor___________rs2236861
ABCB1 C>T______ATP Binding Cassette___________rs1045642
_______________Transporter 1 (ABCB1)

Tests can be ordered as a panel, or individually. ORDER FORM PROVIDED. Customized report with personalized results.

Medical Management Panel

Medical Management

This test may aid in drug selection and dose planning for drugs metabolized by genes in our comprehensive Medical Management Panel: opioid analgesics (buprenorphine, fentanyl, hydrocodone, meperidine, methadone), other common drugs (clonazepam, statins), plavix, warfarin (coumadin), antidepressants, antipsychotic medications, antimalarials, clopidogrel, diazepam, phenytoin, proton pump inhibitors, tamoxifen, beta blockers, anti-arrhythmic, morphine derivatives, xenobiotics, anti-cancer drugs cyclophosphamide and ifosphamide, NNRTI, opiate replacement therapy, anesthetic, protein kinase inhibitor, SERM, catecholamine neurotransmitters dopamine, epinephrine, norepinephrine. It also detects gene variants that affect pain threshold, presence of pain-related disorders (fibromyalgia, TMJ syndrome, migraine), in addition to variants associated with inherited thrombosis.
ABCB1
APOE
COMT
CYP1A2,
CYP2C19
CYP2C9
CYP2D6
CYP1A2
CYP2B6
CYP3A4,
CYP3A5
DRD2
Factor II
Factor V
GLP1R
MTHFR
OPRM1,
PNPLA5
SLCO1B1
SULT4A1
VKORC1

Cardiovascular Panel

Cardiovascular

This test may aid in drug selection and dose planning for drugs metabolized by genes in Cardiovascular Panel: plavix, warfarin (coumadin), beta blockers, anti-arrhythmic, proton pump inhibitors, morphine derivatives, statins, and antidepressants. It also detects variants associated with inherited thrombosis, increased homocysteine and lowered plasma folate levels.
APOE
CYP2C19
CYP2C9
CYP2D6
CYP3A4,
Factor II
Factor V
MTHFR
SLCO1B1
VKORC1

Mental Health Panel

Mental Health

This test may aid in drug selection and dose planning for drugs metabolized by genes in Mental Health Panel: antidepressant and antipsychotic medications.
COMT
CYP1A2
CYP2C19
CYP2C9
CYP2D6
CYP2B6,
DRD2
GLP1R
MTHFR
OPRM1,
PNPLA5
SULT4A1

Pain Management Panel

Pain Management

This test may aid in drug selection and dose planning for drugs metabolized by genes in Pain Management Panel: gene variants that affect pain threshold, presence of pain-related disorders (fibromyalgia, TMJ syndrome, migraine) and others.
COMT
CYP1A2
CYP2C19
CYP2C9
CYP2D6
OPRM1

Thrombosis Risk Panel

Factor II/V/MTHFR

Our Factor II-V & MTHFR Panel is a qualitative in vitro test that detects genotypes of Factor II, Factor V and MTHFR. It is indicated for use as an aid to diagnose patients with suspected thrombophilia. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The most common variant associated with inherited thrombosis is Factor V Leiden G1691A variant. This variant results in resistance to activated protein C. The second most common variant associated with hereditary thrombosis is the G20210A variant in the prothrombin (Factor II) gene. This is associated with increased plasma prothrombin levels.

Increased plasma homocysteine levels is another important risk factor for venous thrombosis. An important genetic variant in the MTHFR gene is C677T the product of which is a thermolabile enzyme and decreased production of folate, a cofactor required for homocysteine remethylation. The MTHFR A1298C variant is also associated with increased homocysteine and lowered plasma folate levels when present in combination with the C677T mutation.

Our test detects the above described variants in each of Factor II, Factor V and MTHFR genes.

Factor II
Factor V
MTHFR

Orthopedic Panel

Orthopedic

This test may aid in drug selection and dose planning for drugs metabolized by genes in Orthopedic Panel: gene variants that affect pain threshold, presence of pain-related disorders (Fibromyalgia, TMJ syndrome), and Inherited Thrombosis.
CYP2C9
CYP2D6
MTHFR
Factor II
Factor V
VKORC1

NeuR Panel

Neurological Response

DRUG SELECTION / DOSE PLANNING

Our NeuR Panel is designed to examine variants indicative of neurological function. It detects allelic variants in Serotonin 2A Receptor, Catechol-O-Methyltransferase, Dopamine D2 Receptor, Dopamine D1 Receptor, Dopamine D4 Receptor, Dopamine Transporter, Dopamine Beta Hydroxylase, Methylene Tetrahydrofolate Reductase, Kappa Opioid Receptor, Gamma Aminibutyric Acid (GABA), Mu Opioid Receptor, Galanin, Delta Opioid Receptor, and ATP Binding Cassette Transporter 1 (ABCB1). These variants are responsible for enzymatic metabolism of catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine. It also detects variants that in genes that affect pain threshold, presence of pain- related disorders (fibromyalgia, TMJ syndrome, migraine) and others.

5-HT2A C>T_____Serotonin 2A Receptor__________rs7997012
COMT _________Catechol-O-Methyltransferase_____rs4680
DRD2 G>A______Dopamine D2 Receptor__________rs1800497
DRD1 A>G______Dopamine D1 Receptor__________rs4532
DRD4 T>C______Dopamine D4 Receptor__________rs3758653
DAT1 A>G______Dopamine Transporter___________rs6347
DBH C>T_______Dopamine Beta Hydroxylase_______rs1611115
MTHFR C>T_____Methylene Tetrahydrofolate_______rs1801133
_______________Reductase
OPRK1 G>T______Kappa Opioid Receptor__________rs1051660
GABA C>A_______Gamma-Aminibutyric Acid (GABA)_rs211014
OPRM1 A>G_____Mu Opioid Receptor_____________rs1799971
MUOR G>A______Mu Opioid Receptor____________rs9479757
GAL T>C________Galanin______________________rs948854
DOR G>A_______Delta Opioid Receptor___________rs2236861
ABCB1 C>T______ATP Binding Cassette___________rs1045642
_______________Transporter 1 (ABCB1)

Plavix Panel

Sensitivity of Individuals to the Drug Plavix

DRUG SELECTION / DOSE PLANNING

This test may aid in drug selection and dose planning for Plavix.

CYP2C19
CYP3A5

Warfarin (Coumadin) Panel

Sensitivity of Individuals to the Drug Warfarin (Coumadin)

DRUG SELECTION / DOSE PLANNING

Our CYP450 2C9-VKORC1 Assay is a qualitative in vitro test that detects mutations in six CYP2C9 genetic variants and seven VKORC1 intronic variants.
This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash to identify the sensitivity of individuals to the drug Warfarin (Coumadin). CYP2C9 influences Warfarin metabolism, whereas VKORC1 plays a role in the pharmacodynamic response in the expression of the enzymatic target of Warfarin (Coumadin).

CYP450 2C9 *2
*3, *4, *5, *6, *11
VKORC1 3673
(-1639G>A)
6009(698C>T)
6484 (1173C>T)
6853 (1542G>T)
7566 (2255C>T)
8773(358C>T)
9041 (3730G>A)
5808 (497T>C)
Analgesic/Anesthesiology
Methadone
Anti-inflammatory
Celecoxib
Diclofenac
Anticoagulant/Antiplatelet
Warfarin
Cardiovascular
Azilsartan
Losartan
Verapamil
Endocrinology
Chlorpropamide
Glimepiride
Glyburide
Nateglinide
Tolbutamide
Infectious Disease
Quinine
Quinine Sulfate
Terbinafine
Neurology
Phenytoin
Oncology
Belinostat
Bortezomib
Gleevec
Imatinib
Urology
Vardenafil
Anticoagulant
Ticlopidine
Cardiovascular
Amiodarone
Fenofibrate
Fluvastatin
Lovastatin
Infectious Disease
Efavirenz
Fluconazole
Isoniazid
Sulfamethoxazole
Voriconazole
Oncology
Nilotinib
Teniposide
Psychiatry
Fluvoxamine
Paroxetine
Sertraline
Pulmonary
Zafirlukast
Gastroenterology
Aprepitant
Infectious Disease
Rifampin
Neurology
Phenobarbital
Oncology
Nilotinib
Sleep Medicine
Secobarbita
Anticoagulant/Antiplatelet
Warfarin VKORC1

CYP450 3A4/3A5

Sensitivity of Individuals to Drugs Metabolized by CYP450 3A4/3A5 Genes

DRUG SELECTION / DOSE PLANNING

Our CYP450 3A4-3A5 Assay is a qualitative in vitro test that detects 13 clinically relevant genetic variants of CYP3A4 and CYP3A5 genes. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.
The CYP3A enzymes metabolize over 40% of the drugs currently approved by the FDA. Of the CYP3A enzymes, CYP3A4 and CYP3A5 are important in drug metabolism due to their abundance in the liver. This assay tests for common variants of CYP3A4 and CYP3A5 that can result in decreased metabolism of certain opioid analgesics (eg, buprenorphine, fentanyl, hydrocodone, meperidine, methadone) and other common drugs (eg, clonazepam and statins). This test may aid in drug selection and dose planning for drugs metabolized by CYP3A4 and CYP3A5.

CYP450 3A4 *1B,
*2, *3, *12
*17, CYP450 3A5
*1D, *2, *3
*3B, *6, *7,*8
and *9
ANTIHISTAMINES
astemizole
chlorpheniramine
ANTIMETRIC
aprepitant
ondansetron
ANESTHESIA/PAIN
cafergot
codeine-N-demethylation
fentanyl
levolevomethadyl acetate (LAAM)
lidocaine,
methadone
ANTIBIOTIC/ANTIVIRAL
alfentanil
boceprevir
clarithromycin
efavirenz
erythromycin (not CYP3A5)
indinavir
nelfinavir
nevirapine
quinine
ritonavir
saquinavir
telaprevir telithromycin.
CARDIOVASCULAR
amlodipine
cilostazol
diltiazem
eplerenone
lercanidipine
nifedipine
nisoldipine
nitrendipine
propranolol
quinidine (not CYP3A5)
verapamil
HMG COA REDUCTASE INHIBITORS
atorvastatin
lovastatin
simvastatin
IMMUNE MODULATORS
cyclosporine
sirolimus
tacrolimus
NEUROPSYCHIATRIC
alprazolam
diazepam
midazolam
triazolam
haloperidol
aripiprazole
buspirone
carbamazepine
pimozide
quetiapine
risperidone
trazodone
zaleplon
ziprasidone
zolpidem
ONCOLOGY
docetaxel
gleevec
irinotecan
paclitaxel
romidepsin
sorafenib
sunitinib
torisel
vemurafenib
vincristine
PULMONARY
salmeterol
sildenafil
STEROID
dexamethasone
estradiol
hydrocortisone
progesterone
testosterone
OTHER
cocaine
dapsone
dextromethorphan
finasteride
nateglinide
cocaine
dapsone
dextromethorphan
finasteride
nateglinide
STRONG INHIBITORS
clarithromycin
indinavir
itraconazole
ketoconazole
nefazodone
ritonavir
saquinavir
suboxone
telithromycin
INTERMEDIATE STRENGTH INHIBITORS
aprepitant
erythromycin
fluconazole
grapefruit juice
verapamil
diltiazem
WEAK INHIBITORS
cimetidine
OTHER POSSIBLE INHIBITORS
amiodarone
boceprevir
chloramphenicol
ciprofloxacin
delaviridine
diethyl-dithiocarbamate
fluvoxamine
gestodene
imatinib
mibefradil
mifepristone
norfloxacin
norfluoxetine
starfruit
telaprevir
voriconazole
barbiturates
carbamazepine
efavirenz
glucocorticoids
modafinil
nevirapine
oxcarbazepine
phenobarbital
phenytoin
pioglitazone
rifabutin
rifabutin
St. John’s Wort
troglitazone

CYP450 2C19

Sensitivity of Individuals to Drugs Metabolized by CYP450 2C19 Gene

DRUG SELECTION / DOSE PLANNING

Our CYP450 2C19 Assay is a qualitative in vitro test that detects mutations in CYP2C19 plus alleles, providing greater than 98% coverage of the variant alleles found for this gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.

This test may aid in drug selection and dose planning for drugs metabolized by CYP2C19 such as Plavix.
Drugs metabolized by CYP2C19 are antidepressants, antimalarials, clopidogrel, diazepam, phenytoin, proton pump inhibitors, R-warfarin, tamoxifen, etc.

CYP450 2C19
*2, *3, *4, *5
*6, *7, *8, *9
*10, *17
Analgesic/Anesthesiology
Methadone
Anticoagulant/Antiplatelet
Clopidogrel
Cardiovascular
Azilsartan
Cilostazol
Labetalol
Propranolol
Verapamil
Gastroenterology
Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Ondansetron
Pantoprazole
Rabeprazole
Infectious Disease
Nelfinavir
Quinine
Quinine Sulfate
Terbinafine
Voriconazole
Neurology
Clobazam
Oncology
Bortezomib
Gleevec
Imatinib
Lapatinib
Psychiatry
Amitriptyline
Citalopram
Clomipramine
Diazepam
Escitalopram
Imipramine
Milnacipran
Sertraline
Trimipramine
Vortioxetine
Rheumatology
Carisoprodol
Tofacitinib
Anesthesiology/Analgesic
Indomethacin
Methadone
Phenylbutazone
Gastroenterology
Cimetidine
Esomeprazole
Lansoprazole
Metoclopramide
Omeprazole
Pantoprazole
Rabeprazole
Infectious Disease
Chloramphenicol
Efavirenz
Isoniazid
Ketoconazole
Voriconazole
Neurology
Eslicarbazepine
Felbamate
Oxcarbazepine
Topiramate
Psychiatry
Fluoxetine
Fluvoxamine
Rheumatology
Probenecid
Sleep Medicine
Modafinil
Infectious Disease
Rifampin
Neurology
Carbamazepine

CYP450 2D6

Sensitivity of Individuals to Drugs Metabolized by CYP450 2D6 Gene

DRUG SELECTION / DOSE PLANNING

Our CYP450 2D6-BC Assay is a qualitative in vitro test that detects mutations in CYP450 2D6. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.
CYP2D6 is one of the most important drug metabolizing enzyme genes as it metabolizes 25% to 30% of all prescribed drugs. Common drug categories metabolized by CYP2D6 include beta blockers, anti-arrhythmic, morphine derivatives, and antidepressants.
This test may aid in drug selection and dose planning for drugs metabolized by CYP450 2D6.

CYP450 2D6 *2
*3, *4, *5, *6,
*7, *8, *9, *10
*12, *14, *17
*29, *41, XN
Analgesic/Anesthesiology
Codeine
Cyclobenzaprine
Hydrocodone
Methadone
Oxycodone
Tramadol
Cardiovascular
Carvedilol
Clonidine
Flecainide
Lidocaine
Metoprolol
Propafenone
Propranolol
Ranolazine
Timolol
Infectious Disease
Quinine
Quinine Sulfate
Neurology
Donepezil
Tetrabenazine
Oncology
Bortezomib
Gleevec
Imatinib
Tamoxifen
Psychiatry
Amitriptyline
Aripiprazole
Atomoxetine
Brexpiprazole
Buproprion
Clomipramine
Clozapine
Desipramine
Diazepam
Doxepin
Duloxetine
Fluoxetine
Fluvoxamine
Haloperidol
Iloperidone
Imipramine
Milnacipran
Nortriptyline
Olanzapine
Paroxetine
Perphenazine
Pimozide
Protriptyline
Quetiapine
Risperidone
Thioridazine
Trimipramine
Venlafaxine
Vortioxetine
Rheumatology
Cevimeline
Urology
Tamsulosin
Tolterodine
Allergy
Chlorpheniramine
Clemastine
Diphenhydramine
Hydroxyzine
Anesthesiology/Analgesic
Celecoxib
Dexmedetomidine
Anticoagulant
Ticlopidine
Cardiovascular
Amiodarone
Dronedarone
Midodrine
Quinidine
Drug of Abuse
Cocaine
Endocrinology
Cinacalcet
Endocrinology
Cimetidine
Ranitidine
Infectious Disease
Quinine Sulfate
Ritonavir
Terbinafine
Oncology
Doxorubicin
Nilotinib
Pazopanib
Psychiatry
Bupropion
Chlorpromazine
Citalopram
Clomipramine
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Haloperidol
Paroxetine
Sertraline
Infectious Disease
Rifampin

CYP450 2B6

Sensitivity of Individuals to Drugs Metabolized by CYP450 2B6 Gene

DRUG SELECTION / DOSE PLANNING

Our CYP450 2B6 QUAD-96 Assay is a qualitative in vitro test that detects 7 genetic variants of the CYP2B6 gene. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash. It can detect and identify the following allelic variants: 64C>T, 983T>C, 415 A>G, 1132 C>T, 516 G>T, 1459 C>T, 785 A>G.
The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide, opioid analgesic, antidepressants, NNRTI, opiate replacement therapy, anesthetic, protein kinase inhibitor, SERM, and others.

64C>T
983T>C
415 A>G
1132 C>T
516 G>T
1459 C>T
785 A>G

CYP450 1A2

Sensitivity of Individuals to Drugs Metabolized by CYP450 1A2 Gene

DRUG SELECTION / DOSE PLANNING

Our CYP450 1A2-96 Assay is a qualitative in vitro test that is designed to detect mutations in the CYP1A2 gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.

It is designed to detect and identify three allelic variants in the CYP450 1A2 gene.
This gene affects the metabolism of common antidepressant and antipsychotic medications.

3860G>A
163C>A
2467delT

ApoE

Sensitivity of Individuals to Statins

DRUG SELECTION / DOSE PLANNING

Our ApoE QUAD Assay is a qualitative in vitro test that is designed to detect mutations in the ApoE gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash. It can detect and identify the following allelic variants in the ApoE gene: 388T>C and 526C>T and report the predicte isoforms on the high throughput system.
The predicted isoform call can be: [E3,E3], [E2,E3], [E2,E2], [E3,E4], [E4,E4], or [E2,E4].

These genetic variants affect the response to statins.

If you have any questions about Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC – CLIA Certified Laboratory) Pharmacogenetic Testing, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.